Fluconazole reshapes the gut microbiome and improves disease activity in IBD
In a prospective study of 53 patients with mild-to-moderate inflammatory bowel disease (UC or Crohn’s), fluconazole reduced gut Candida burden and reshaped the fungal community, triggering cross-kingdom shifts that increased bacterial diversity and boosted butyrate-producer and anti-inflammatory metabolites, correlating with improved disease activity over 8 weeks; oral nystatin did not have these effects, suggesting mycobiome-targeted antifungal therapy may help IBD management.